Skip to main content
. 2021 Jun 22;2021:6639366. doi: 10.1155/2021/6639366

Table 3.

Association between the KRAS status and HPD for patients with colorectal cancer treated with immunotherapy (n, %).

Colorectal cancer Non-HPD (n = 17) HPD (n = 5) P
KRAS mutation 0.039
 Mutated type 4 (23.5) 4 (80.0)
 Wild type 13 (76.5) 1 (20.0)

HPD: hyperprogressive disease.